Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3803-3811

  Scotto, Luigi ^a   Kruithof De Julio, Marianna ^a   Paoluzzi, Luca ^b   Kalac, Matko ^b   Marchi, Enrica ^a   Buitrago, Jairo Baquero ^b   Amengual, Jennifer ^a   Shen, Michael M ^a   O'Connor, Owen A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; DEXAMETHASONE; LUCIFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BIOLUMINESCENCE; CANCER GROWTH; CONTROLLED STUDY; DRUG RESPONSE; EMBRYO; EX VIVO STUDY; FLUORESCENCE ANALYSIS; GENE LOCUS; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; FLUORESCENCE; HEK293 CELLS; HUMANS; LUCIFERASES; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; RECOMBINANT PROTEINS;

EID: 84863890062     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2588     Document Type: Article

References (21)

1. Garber K. Realistic rodents? Debate grows over new mouse models of cancer. J Natl Cancer Inst 2006;98:1176-8.
2. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54. (Pubitemid 44323701)
3. Abate-Shen C. A new generation of mouse models of cancer for translational research. Clin Cancer Res 2006;12:5274-6. (Pubitemid 44497239)
4. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res 2006;12:5312-28. (Pubitemid 44497244)
5. McCaffrey A, Kay MA, Contag CH. Advancing molecular therapies through in vivo bioluminescent imaging. Mol Imaging 2003;2:75-86.
6. Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, Buckle T, et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 2007;43:7-13, 30.
7. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101: 640-8. (Pubitemid 36077588)
8. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000;2:491-5. (Pubitemid 32098683)
9. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002;62:1862-7. (Pubitemid 34408514)
10. Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. Nat Methods 2005;2:905-9. (Pubitemid 43108726)
11. Stanisławska-Sachadyn A, Sachadyn P, Jedrzejczak R, Kur J. Construction and purification of his6-Thermus thermophilus MutS protein. Protein Expr Purif 2003;28:69-77. (Pubitemid 36453180)
12. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352-5.
13. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol 1989;143:712-7. (Pubitemid 19191574)
14. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, et al. Burkitt lymphoma in the mouse. J Exp Med 2000; 192:1183-90.
15. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008;40:108-12.
16. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995;3:39-50.
17. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32.
18. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003;20:733-44. (Pubitemid 38019275)
19. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3Mluc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003;20:745-56. (Pubitemid 38019276)
20. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S, et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006; 58:365-72. (Pubitemid 43212802)
21. El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. Combined noninvasive imaging and luminometric quantification of luciferaselabeled human prostate tumors and metastases. Lab Invest 2002; 82:1563-71. (Pubitemid 35332915)